Search results for "NAD"

showing 10 items of 2033 documents

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vi…

2007

Objective: To investigate the effects of recombinant (r-) LH supplementation in “low responder” patients undergoing ovarian stimulation with r-FSH for an IVF program. The apoptosis rate in cumulus cells was used as an indicator of oocyte quality. Design: Comparison of the rate of DNA fragmentation and caspase-3 activity in cumulus cells in women stimulated with r-LH and r-FSH, versus patients treated with r-FSH alone (control). Setting: In vitro fertilization (IVF) laboratory. Patient(s): Forty patients undergoing assisted fertilization programs treated with a GnRH agonist, or r-FSH treatment begun on day 3 of the cycle (control). In the r-LH group, from day 8 of gonadotropin stimulation, 1…

Adultendocrine systemmedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentOvaryApoptosisDNA FragmentationFertilization in VitroBiologyOvulation InductionPregnancyInternal medicinemedicineIn Situ Nick-End LabelingHumansrecombinant LHOvarian follicleimplantation rateHuman cumulus cells; apoptosis; IVF; pregnancy rate; implantation rate; recombinant LH; oocyte qualityIn vitro fertilisationGranulosa CellsCaspase 3Obstetrics and GynecologyLuteinizing HormoneOocyteCumulus oophorusapoptosiRecombinant ProteinsPregnancy ratemedicine.anatomical_structureEndocrinologyHuman cumulus cellReproductive MedicineIVFFemaleoocyte qualityGonadotropinFollicle Stimulating HormoneLuteinizing hormonehormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

Gonadotropin-releasing hormone (GnRH)-I regulation of interleukin (IL)-1b and IL-1 receptor antagonist expression in cultured human endometrial strom…

2008

Aim:  Human endometrium is an active site of cytokine production and action. Among these cytokines, the interleukin-1 (IL-1) system seems to be relevant to the embryonic implantation process. We have previously reported the production of GnRH-I by human blastocyst, as well as the presence of GnRH-I receptor in human endometrium. This suggests a close interaction between the immune and endocrine systems through these cytokine mediators in embryonic implantation. Methods:  To test the relevance of this interaction during embryonic implantation, we investigated GnRH-I regulation of IL-1b and IL-1ra mRNA and protein expression in human endometrial stromal cells using quantitative competitive po…

Adultendocrine systemmedicine.medical_specialtyStromal cellmedicine.drug_classmedicine.medical_treatmentInterleukin-1betaGonadotropin-releasing hormoneBiologyEndometriumGonadotropin-Releasing HormoneEndometriumInternal medicinemedicineHumansEmbryo ImplantationRNA MessengerBlastocystProtein PrecursorsReceptorObstetrics and GynecologyInterleukinReceptor antagonistInterleukin 1 Receptor Antagonist ProteinEndocrinologymedicine.anatomical_structureCytokineFemaleStromal Cellshormones hormone substitutes and hormone antagonistsJournal of Obstetrics and Gynaecology Research
researchProduct

High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist.

2011

High daily doses of gonadotrophin-releasing hormone (GnRH) antagonists during the follicular phase of ovarian stimulation were associated with low implantation rates. To test if this occurred because of profound pituitary suppression, the pituitary response was suppressed with a high-dose GnRH antagonist and recombinant LH (rLH) was added back to correct the implantation rate. An open-label, randomized, controlled, prospective clinical study in 60 patients undergoing IVF was performed. GnRH antagonist was initiated on day 6 of stimulation (2 mg/day) together with 375 IU rLH, and maintained until the day of HCG administration. Controls received 0.25 mg/day GnRH antagonist. Fluctuating LH con…

Adultendocrine systemmedicine.medical_specialtymedicine.medical_treatmentStimulationlaw.inventionGonadotropin-Releasing HormoneOvulation InductionlawInternal medicineFollicular phaseMedicineHumansProspective StudiesAdverse effectProspective cohort studyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyLuteinizing HormoneRecombinant ProteinsDose–response relationshipEndocrinologyReproductive MedicineRecombinant DNAOvulation inductionFemalebusinesshormones hormone substitutes and hormone antagonistsDevelopmental BiologyHormoneReproductive biomedicine online
researchProduct

Hereditary angioedema in children and adolescents - A consensus update on therapeutic strategies for German-speaking countries.

2020

Background/methods At a consensus meeting in August 2018, pediatricians and dermatologists from German-speaking countries discussed the therapeutic strategy for the treatment of pediatric patients with type I and II hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) for Germany, Austria, and Switzerland, taking into account the current marketing approval status. HAE-C1-INH is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life-threatening angioedema. Diagnosis as early as possible and an optimal management of the disease are important to avoid ineffective therapies and to properly treat swelling attacks. This art…

Adultmedicine.medical_specialtyAdolescentImmunology610610 Medicine & healthLanadelumabDiseaseC1-inhibitorGermanPlasma03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIcatibantGermanymedicineHumansImmunology and Allergy030212 general & internal medicineAngioedemaChildIntensive care medicine610 Medicine & healthAngioedemabiologytreatmentbusiness.industryAngioedemas HereditaryC1-INH (C1 inhibitor)medicine.diseaselanguage.human_languagehereditary angioedemapediatric030228 respiratory systemchemistryconsensusPediatrics Perinatology and Child HealthHereditary angioedemalanguagebiology.proteinmedicine.symptombusinessComplement C1 Inhibitor Protein600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und GesundheitRare disease
researchProduct

Extracorporeal circuit heparinization in selective low density lipoprotein apheresis: changes in patient hemostasis and low molecular weight heparin …

1993

Treatment by low density lipoprotein (LDL) apheresis using dextran sulfate columns (DSC) leads to hemostasis alterations with prolonged activated partial thromboplastin time (APTT) of more than 120 seconds. In order to explain this hypocoagulability, we studied hemostasis parameters both in patients and in the extracorporeal circulation (ECC). Hemostasis changes are first related to unfractionated heparin (UFH)—needed to avoid circuit coagulation—which leads to high residual heparinemia in the patient (more than 3 times the recommended level for therapeutic use). Second, the hypocoagulability is induced by a coagulation factor decrease (primarily factors V, VIH, and X) mainly due to an adso…

Adultmedicine.medical_specialtyExtracorporeal Circulationmedicine.drug_classLow molecular weight heparinHyperlipoproteinemia Type IIInternal medicinemedicineHumansHemostasismedicine.diagnostic_testbusiness.industryExtracorporeal circulationAnticoagulantDextran SulfateNadroparinHematologyGeneral MedicineHeparinMiddle AgedBlood Coagulation FactorsSurgeryLipoproteins LDLApheresisLDL apheresisHemostasisCardiologyBlood Component RemovalbusinessPartial thromboplastin timemedicine.drugJournal of clinical apheresis
researchProduct

Maternal serum ghrelin levels in early IVF pregnancies: lack of prognostic value for viable pregnancy and altered post-prandial responses

2008

Background Ghrelin is a pleiotropic hormone, involved in the control of growth and metabolism, whose circulating levels fluctuate in relation to food intake and body mass index. Ghrelin has been detected in the decidualized endometrium, as well as in human and rat placenta. Methods A total of 106 patients undergoing IVF procedures were prospectively recruited. On Days 16 and 23 after oocyte retrieval, the patients were subjected to blood sampling after overnight fasting, for determination of serum ghrelin, hCGbeta and progesterone levels. In addition, ghrelin levels were assayed in these groups, 2 h after ingestion of a fixed-calorie meal. Results The subjects were divided according to whet…

Adultmedicine.medical_specialtyFertilization in VitroBiologyEndometriumBody Mass IndexPregnancyInternal medicinemedicineHumansIngestionChorionic Gonadotropin beta Subunit HumanProspective StudiesProgesteronePregnancydigestive oral and skin physiologyRehabilitationPregnancy OutcomeObstetrics and GynecologyGestational ageFastingPostprandial PeriodPrognosismedicine.diseaseGhrelinEndocrinologymedicine.anatomical_structurePostprandialReproductive MedicineFemaleGhrelinhormones hormone substitutes and hormone antagonistsBlood samplingHormoneHuman Reproduction
researchProduct

Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major

2002

We studied bone mass and metabolism in 30 adult women (age 28.5 +/- 1.3) with thalassemia major (TM) and evaluated whether prolonged hormone replacement therapy (HRT) was able to optimize bone accrual. TM patients had reduced bone mass, increased bone turnover and lower serum gonadotropin and estradiol levels compared with 10 normal women of similar age. A significant correlation was found between bone mass and sex hormone levels. Six TM patients with normal ovarian function had normal bone turnover markers and modestly low bone mass (lumbar spine -1.29 +/- 0.31; femoral neck -0.60+/-0.21; Z-score). The other 24 TM women were hypogonadic and had significantly lower bone mass for age (lumbar…

Adultmedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and MetabolismThalassemiaOsteoporosisBone remodelingAdult womenEndocrinologySex hormone-binding globulinBone DensityInternal medicinemedicineHumansOrthopedics and Sports MedicineFemoral neckEstradiolbiologybusiness.industryHypogonadismbeta-ThalassemiaOsteoporosiLuteinizing Hormonemedicine.diseaseThalassaemiaEndocrinologymedicine.anatomical_structureTransgender hormone therapyOrthopedic surgerybiology.proteinFemaleFollicle Stimulating HormonebusinessCalcified Tissue International
researchProduct

Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pill pretreatment.

2007

Objective To evaluate and compare the risk of early pregnancy loss in patients stimulated with GnRH antagonist protocols according to oral contraceptive pill (OCP) pretreatment. Design Retrospective case–control study. Setting Instituto Valenciano de Infertilidad. University of Valencia. Spain. Patient(s) One thousand five hundred thirty-nine patients, aged Intervention(s) Reproductive outcome was compared based on the application (or not) of OCP pretreatment: 944 women were included in the OCP group and 595 in the non-OCP group. The Student's t test was used for statistics. Main Outcome Measure(s) Pregnancy, biochemical pregnancy, ectopic pregnancy, early clinical pregnancy loss, early pre…

Adultmedicine.medical_specialtyOral contraceptive pillPregnancy Ratemedicine.drug_classEarly Pregnancy LossGonadotropin-releasing hormone antagonistMiscarriageGonadotropin-Releasing HormonePregnancymedicineHumansRetrospective StudiesGynecologyPregnancyEctopic pregnancybusiness.industryObstetrics and Gynecologymedicine.diseasePregnancy rateReproductive MedicinePillCase-Control StudiesEmbryo LossFemalebusinessContraceptives OralFertility and sterility
researchProduct

Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial

2013

Abstract Background Both oral contraceptive pills (OCPs) and estradiol (E2) valerate have been used to schedule gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between GnRH antagonist IVF cycles scheduled with OCPs or E2 valerate. Methods Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women 18–38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts)…

Adultmedicine.medical_specialtyPregnancy Ratemedia_common.quotation_subjectPopulationPhysiologyFertilization in VitroCycle schedulingReproductive technologyGonadotropin-releasing hormoneValerateContraceptives Oral Hormonallaw.inventionGonadotropin-Releasing HormoneEndocrinologyRandomized controlled trialPregnancylawInternal medicineGnRH antagonistHumansMedicineeducationMenstrual CycleMenstrual cyclemedia_commonchemistry.chemical_classificationeducation.field_of_studyEstradiolOral contraceptivesbusiness.industryResearchEstradiol valerateEstrogen pretreatmentObstetrics and GynecologyPregnancy rateEndocrinologychemistryReproductive MedicineIVFFemalebusinessmedicine.drugDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 400…

2010

background: The influence of elevated serum progesterone levels during in vitro fertilization/intracytoplasmic sperm injection (IVF/ ICSI) cycles on pregnancy rates is a matter of continued debate among fertility clinicians. Efforts to resolve this question have been impeded by the various assays used to measure progesterone and the different, arbitrary threshold values for defining ‘high’ progesterone levels. methods: A non-interventional, retrospective, observational, single-centre cohort study evaluated the relationship between serum progesterone levels on the day of human chorionic gonadotrophin (hCG) administration and the ongoing pregnancy rate in 4032 patients undergoing IVF/ICSI cyc…

Adultmedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentFertilityStimulationFertilization in VitroGonadotropin-releasing hormoneBiologyChorionic GonadotropinIntracytoplasmic sperm injectionCohort StudiesGonadotropin-Releasing HormoneAndrologyOvulation InductionPregnancyInternal medicinemedicineHumansProgesteroneRetrospective Studiesmedia_commonPregnancyIn vitro fertilisationbusiness.industryRehabilitationObstetrics and GynecologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseConfidence intervalPregnancy rateEndocrinologyReproductive MedicineRegression AnalysisReproductive Control AgentsGestationFemaleOvulation inductionFollicle Stimulating HormoneGonadotropinbusinesshormones hormone substitutes and hormone antagonistsHormoneHuman Reproduction
researchProduct